Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference – Biogen

1. Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference  Biogen
2. Two Alzheimer Disease Therapies to Watch at CTAD 2025: Lecanemab and Sabirnetug Updates  Patient Care Online
3. How New Lecanemab Data Releases at CTAD 2023 Could Shape BioArctic’s (OM:BIOA B) Investment Case  simplywall.st
4. Bioarctic’s Partner to Present New Lecanemab Results at CTAD Conference  MarketScreener
5. Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference  BioSpace

Continue Reading